journal
MENU ▼
Read by QxMD icon Read
search

Annals of Pharmacotherapy

journal
https://www.readbyqxmd.com/read/28645216/iglarlixi-a-fixed-ratio-combination-of-insulin-glargine-100-u-ml-and-lixisenatide-for-the-treatment-of-type-2-diabetes
#1
Jennifer Goldman, Jennifer M Trujillo
OBJECTIVE: To review the safety and efficacy of iGlarLixi, a titratable fixed-ratio combination of insulin glargine 100 U/mL (iGlar) and lixisenatide, a glucagon-like peptide-1 receptor agonist. DATA SOURCES: A literature search of MEDLINE for all English-language primary articles through June 2016, using the terms LixiLan, iGlarLixi and insulin glargine and lixisenatide, and a search of abstracts presented at the 2016 Scientific Sessions of the American Diabetes Association were performed...
June 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28643558/influence-of-anthropometric-characteristics-in-patients-with-her2-positive-breast-cancer-on-initial-plasma-concentrations-of-trastuzumab
#2
Jonathan González García, Fernando Gutiérrez Nicolás, Gloria Julia Nazco Casariego, José Norberto Batista López, Isaac Ceballos Lenza, Ruth Ramos Díaz, Matías Llabrés Martínez
BACKGROUND: Plasma concentrations of trastuzumab <20 µg/mL in patients with gastric cancer are associated with reduced progression-free and overall survival. In breast cancer treatment, this relationship has not yet been studied, but a suboptimal pharmacodynamic exposure to trastuzumab could be a reason for therapeutic failure of treatment of HER2-positive breast cancer. OBJECTIVE: The objective of the present study was to determine the proportion of nonmetastatic HER2-positive breast cancers that do not reach a minimum plasma concentration ( Cmin) of 20 µg/mL after first drug administration, established as therapeutically effective in clinical trials...
June 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28643524/a-multicenter-retrospective-analysis-of-factors-associated-with-apixaban-related-bleeding-in-hospitalized-patients-with-end-stage-renal-disease-on-hemodialysis
#3
Taylor D Steuber, Dane L Shiltz, Alex C Cairns, Qian Ding, Katie J Binger, Julia R Courtney
BACKGROUND: In 2014, the United States Food and Drug Administration approved a labeling change for apixaban to include recommendations for patients with severe renal impairment and patients with end-stage renal disease (ESRD) on hemodialysis (HD), though these recommendations are largely based on pharmacokinetic and pharmacodynamic data. OBJECTIVE: Identify variables associated with bleeding events in hospitalized patients with ESRD on HD receiving apixaban. METHODS: This retrospective, multicenter cohort study evaluated hospitalized patients with ESRD on HD receiving apixaban from January 1, 2013, through March 31, 2016...
June 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28639882/management-of-oral-anticoagulation-therapy-after-gastrointestinal-bleeding-whether-to-when-to-and-how-to-restart-an-anticoagulation-therapy
#4
Kazuhiko Kido, Michael J Scalese
OBJECTIVE: To evaluate current clinical evidence for management of oral anticoagulation therapy after gastrointestinal bleeding (GIB) with an emphasis on whether to, when to, and how to resume an anticoagulation therapy. DATA SOURCES: Relevant articles from MEDLINE, Cochrane Library, and EMBASE databases were identified from 1946 through May 20, 2017, using the keywords: gastrointestinal hemorrhage or gastrointestinal bleeding and antithrombotic therapy or anticoagulation therapy or warfarin or dabigatran or rivaroxaban or apixaban or edoxaban...
June 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28635299/prevalence-and-geographic-variations-of-polypharmacy-among-west-virginia-medicaid-beneficiaries
#5
Xue Feng, Xi Tan, Brittany Riley, Tianyu Zheng, Thomas K Bias, James B Becker, Usha Sambamoorthi
BACKGROUND: West Virginia (WV) residents are at high risk for polypharmacy given its considerable chronic disease burdens. OBJECTIVE: To evaluate the prevalence, correlates, outcomes, and geographic variations of polypharmacy among WV Medicaid beneficiaries. METHODS: In this cross-sectional study, we analyzed 2009-2010 WV Medicaid fee-for-service (FFS) claims data for adults aged 18-64 (N=37,570). We defined polypharmacy as simultaneous use of drugs from five or more different drug classes on a daily basis for at least 60 consecutive days in one year...
June 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28627271/vancomycin-trough-concentration-poorly-characterizes-auc-is-it-time-to-transition-to-auc-based-vancomycin-monitoring
#6
Robert W Seabury, Andrew M Stoessel, Jeffrey M Steele
No abstract text is available yet for this article.
June 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28627235/translating-guidelines-into-practice-interpreting-the-2016-acc-expert-consensus-decision-pathway-on-the-role-of-non-statin-therapies-for-ldl-cholesterol-lowering-in-the-management-of-atherosclerotic-cardiovascular-disease-risk
#7
Laura H Waite, Yvonne L Phan, Sarah A Spinler
OBJECTIVE: In 2016, the American College of Cardiology released a decision pathway, based on expert consensus, to guide use of non-statin agents in the management of atherosclerotic cardiovascular disease risk. The purpose of this article is to assist practitioners, health systems and managed care entities with interpreting this consensus statement in order to simplify implementation of the recommendations into patient care. METHODS: Major themes from the consensus statement are briefly summarized and explained...
June 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28627229/cobicistat-versus-ritonavir-similar-pharmacokinetic-enhancers-but-some-important-differences
#8
Alice Tseng, Christine A Hughes, Janet Wu, Jason Seet, Elizabeth J Phillips
OBJECTIVE: To describe properties of cobicistat and ritonavir; compare boosting data with atazanavir, darunavir, and elvitegravir; and summarize antiretroviral and comedication interaction studies, with a focus on similarities and differences between ritonavir and cobicistat. Considerations when switching from one booster to another are discussed. DATA SOURCES: A literature search of MEDLINE was performed (1985 to April 2017) using the following search terms: cobicistat, ritonavir, pharmacokinetic, drug interactions, booster, pharmacokinetic enhancer, HIV, antiretrovirals...
June 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28627222/reply-extensive-bruising-and-elevated-rivaroxaban-plasma-concentration-in-a-patient-receiving-cobicistat-boosted-elvitegravir
#9
Deborah Yoong, Mark Naccarato, Kevin Gough
No abstract text is available yet for this article.
June 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28608723/non-health-care-facility-cardiovascular-medication-errors-in-the-united-states
#10
Amrit K Kamboj, Henry A Spiller, Marcel J Casavant, Nichole L Hodges, Thiphalak Chounthirath, Gary A Smith
BACKGROUND: Prior studies have not examined national trends and characteristics of unintentional non-health care facility (HCF) medication errors associated with cardiovascular drugs. OBJECTIVE: To investigate non-HCF medication errors associated with cardiovascular drugs reported to poison control centers in the United States. METHODS: A retrospective analysis of non-HCF medication errors associated with cardiovascular drugs from 2000 to 2012 was conducted using the National Poison Data System database...
June 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28608722/comparative-analysis-of-inpatient-costs-for-obstetrics-and-gynecology-surgery-patients-treated-with-iv-acetaminophen-and-iv-opioids-versus-iv-opioid-only-analgesia-for-postoperative-pain
#11
Ryan N Hansen, An T Pham, Belinda Lovelace, Stela Balaban, George J Wan
BACKGROUND: Recovery from obstetrics and gynecology (OB/GYN) surgery, including hysterectomy and cesarean section delivery, aims to restore function while minimizing hospital length of stay (LOS) and medical expenditures. OBJECTIVE: Our analyses compare OB/GYN surgery patients who received combination intravenous (IV) acetaminophen and IV opioid analgesia with those who received IV opioid-only analgesia and estimate differences in LOS, hospitalization costs, and opioid consumption...
June 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28608718/apocalypse-now
#12
Michael T Rupp
Despite the wishful thinking of those who have long prophesied an imminent surge in demand for clinical pharmacists, the tipping point for healthy supply-demand balance in pharmacy has almost certainly been surpassed. Imprudent overbuilding of pharmacy programs has combined with trends toward increasing automation and consolidation in pharmacy practice to create an existential threat in pharmacy education. Surviving the looming industry shakeout will require schools and colleges of pharmacy to do what our colleagues in practice and the private sector have always done: compete...
June 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28602140/enterovaginal-fistula-after-tofacitinib-administration
#13
Cengiz Korkmaz, Döndü U Cansu, Mahmut Kebapcı
No abstract text is available yet for this article.
June 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28599601/effect-of-pharmacy-supported-transition-of-care-interventions-on-30-day-readmissions-a-systematic-review-and-meta-analysis
#14
Claire R Rodrigues, Amanda R Harrington, Nicole Murdock, John T Holmes, Eliza Z Borzadek, Kristin Calabro, Jennifer Martin, Marion K Slack
OBJECTIVE: To describe pharmacy-supported transition-of-care (TOC) interventions and determine their effect on 30-day all-cause readmissions. DATA SOURCES: MEDLINE/PubMed, EMBASE, International Pharmaceutical Abstracts, ABI Inform Complete, PsychINFO, Web of Science, Academic Search Complete, CINHAL, Cochrane library, OIASTER, ProQuest Dissertations & Theses, ClinicalTrials.gov , and relevant websites were searched from January 1, 1995, to December 31, 2015. STUDY SELECTION AND DATA EXTRACTION: PICOS+E criteria were utilized...
June 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28597691/safety-and-efficacy-of-pegfilgrastim-when-given-less-than-14-days-before-the-next-chemotherapy-cycle-retrospective-review-of-every-14-day-chemotherapy-regimen-containing-5-fu-continuous-infusion
#15
Kofi N Donkor, Julie H Selim, Ariani Waworuntu, Kelsey Lewis
BACKGROUND: Pegfilgrastim should not be given <14 days from the next chemotherapy because of concerns for cytopenias. Some clinicians are prescribing pegfilgrastim to be given <14 days in patients receiving 5-fluorouracil continuous infusion (5-FUCI) regimens. OBJECTIVE: To determine the effectiveness and safety of pegfilgrastim administered <14 days from the next chemotherapy in patients receiving 5-FUCI administered >46 hours. METHODS: Single-institution retrospective cohort study of patients who received 5-FUCI administered >46 hours from June 2013 to December 2015...
June 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28592148/use-of-intravenous-lidocaine-for-the-treatment-of-acute-pain-in-the-emergency-department
#16
Jennifer Wiafe, Billy Sin, Adam Kramer, Ramy Yakobi
No abstract text is available yet for this article.
June 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28582998/comparison-of-levetiracetam-dosing-regimens-in-end-stage-renal-disease-patients-undergoing-intermittent-hemodialysis
#17
Harn J Shiue, Maria Taylor, Kara A Sands
BACKGROUND: Levetiracetam (LEV) is primarily renally eliminated. In end-stage renal disease (ESRD) patients on hemodialysis (HD), pharmacokinetic studies recommend daily dosing with 50% supplemental doses after 4-hour HD sessions. However, poor medication adherence after HD could result in fluctuating plasma drug levels. OBJECTIVE: To compare two LEV dosing regimens, daily versus twice-daily (BID), in ESRD patients undergoing HD. METHODS: Consecutive ESRD patients (April 2013 to May 2014) receiving maintenance inpatient HD and prescribed LEV prior to admission to our academic tertiary hospital were prospectively analyzed...
June 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28573932/efficacy-and-safety-of-uninterrupted-low-intensity-warfarin-for-radiofrequency-catheter-ablation-of-atrial-fibrillation-in-the-elderly-a-pilot-study
#18
Yangbo Xing, Buyun Xu, Chao Xu, Fang Peng, Biao Yang, Yufang Qiu, Yong Sun, Shengkai Wang, Hangyuan Guo
BACKGROUND: No previous studies exist investigating the optimal intensity of uninterrupted anticoagulation with warfarin during radiofrequency catheter ablation (RFCA) for atrial fibrillation (AF) in the elderly. OBJECTIVE: Evaluate the efficacy and safety of continuous low-intensity warfarin therapy throughout the periprocedural period of RFCA for AF in the elderly. METHODS: This is a prospective randomized study. We enrolled AF patients (age ≥ 70 years) who underwent first-time RFCA for AF...
June 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28573879/does-cardiovascular-comorbidity-influence-the-prescribing-of-bronchodilators-in-chronic-obstructive-pulmonary-disease
#19
Damilola T Adesanoye, Cynthia J Willey
BACKGROUND: Cardiovascular disease (CVD) is the most prevalent comorbidity for chronic obstructive pulmonary disease (COPD). Potential adverse cardiovascular events of bronchodilators warrant their cautionary use in the comorbid COPD-CVD population, yet little is known about the prescribing of bronchodilators in this high-risk patient group. OBJECTIVE: To determine whether comorbid CVD is associated with reduced bronchodilator prescribing in patients with COPD. In addition, we explored how the association was modified by gender, concurrent asthma, and concomitant β-blocker (BB) use...
June 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28573873/impact-of-diabetes-care-by-pharmacists-as-part-of-health-care-team-in-ambulatory-settings-a-systematic-review-and-meta-analysis
#20
Maryam T Fazel, Alaa Bagalagel, Jeannie K Lee, Jennifer R Martin, Marion K Slack
OBJECTIVE: To conduct a comprehensive systematic review and meta-analyses examining the impact of pharmacist interventions as part of health care teams on diabetes therapeutic outcomes in ambulatory care settings. DATA SOURCES: PubMed/MEDLINE, EMBASE, Cochrane Library, International Pharmaceutical Abstracts, Web of Science, Scopus, WHO's Global Health Library, ClinicalTrials.gov , and Google Scholar were searched (1995 to February 2017). Search terms included pharmacist, team, and diabetes...
June 1, 2017: Annals of Pharmacotherapy
journal
journal
20312
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"